Isolation and Characterization of a Class II A-Mannosidase Cdna from Lepidopteran Insect Cells

Total Page:16

File Type:pdf, Size:1020Kb

Isolation and Characterization of a Class II A-Mannosidase Cdna from Lepidopteran Insect Cells Glycobiology vol. 7 no. 1 pp. 113-127, 1997 Isolation and characterization of a class II a-mannosidase cDNA from lepidopteran insect cells Donald LJarvis2, Dwight A.Bohlmeyer, Yung-Feng Introduction Liao1, Kristen K.Lomax, Roberta K.Merkle1, Carla 1 Weinkauf and Kelley W.Moremen Lepidopteran insect cells are used widely as hosts for foreign Department of Entomology and Center for Advanced Invertebrate Molecular gene expression by recombinant baculoviruses and, like bac- Sciences, Texas A&M University, College Station, TX 77843, USA and terial expression systems, the insect cell-baculovirus system 'Department of Biochemistry and Molecular Biology and Complex can provide high levels of foreign gene expression (Summers Carbohydrate Research Center, University of Georgia, Athens, GA 30602, and Smith, 1987; Miller, 1988; O'Reilly et al., 1992). The USA Downloaded from https://academic.oup.com/glycob/article/7/1/113/725524 by guest on 01 October 2021 insect ceU-baculovirus system also has eukaryotic protein pro- ^o whom correspondence should be addressed cessing capabilities and, therefore, is one of the best tools Lepidopteran insect cells are used routinely as hosts for currently available for foreign glycoprotein production. How- foreign glycoprotein expression by recombinant baculovi- ever, the nature of the N-glycosylation pathway in lepidopteran ruses, but the precise nature of their N-glycosylation path- insect cells and, particularly, in baculovirus-infected lepidop- way remains poorly defined. These cells clearly have pro- teran insect cells, remains poorly defined. cessing glucosidases and mannosidases that can convert By comparison, the N-glycosylation pathway in higher eu- caryotes is well-defined (reviewed by Kornfeld and Kornfeld, precursors to Man3GlcNAc2 structures and fucosyltrans- ferases that can add fucose to the oligosaccharide core. 1985). This pathway begins with the cotranslational transfer of However, their ability to extend these structures to produce preformed GlCjMangGlcNAcj oligosaccharides from a doli- complex side chains like those found in mammalian cells chol-linked precursor to nascent polypeptide chains on the lu- remains to be determined. To begin to examine this path- minal face of the endoplasmic reticulum (ER), followed by way at the molecular genetic level, we isolated and charac- immediate trimming of glucose residues within the ER. Addi- terized a class II ot-mannosidase (a-mannosidase II) cDNA tional trimming of glucose residues and as many as three of the from Sf9, a lepidopteran insect cell line. In mammalian nine mannose residues can occur within the ER. As glycopro- cells, this enzyme catalyzes the committed step in the path- teins transit the Golgi complex, the last a-l,2-linked mannose way converting N-linked carbohydrates to complex forms. residues are removed by 'class F ot-mannosidases, producing a Degenerate primers against conserved regions in known Man5GlcNAc2 structure (Moremen et al., 1994). Following the class II a-mannosidase protein sequences were used to gen- addition of a single GlcNAc residue by GlcNAc transferase I, erate an a-mannosidase H-specific PCR product from Sf9 two more mannose residues are removed by Golgi a-manno- cell DNA. Sequence information from this product was sidase II, a 'class II' mannosidase (Moremen et al, 1994). This used to isolate a partial cDNA clone, the 5' end was isolated is the committed step in the synthesis of complex type oligo- by ligation-anchored PCR, and the full length a-mannosi- saccharides, which are subsequently produced by Golgi glyco- dase II cDNA was assembled. This cDNA contained a long syltransferases that extend the trimmed structures by adding open reading frame predicted to encode an 1130 amino acid N-acetylglucosamine, galactose, fucose, and sialic acid resi- protein with 37% identity to human Golgi a-mannosidase dues (reviewed by Komfeld and Komfeld, 1985; Paulson and II and with a type II membrane topology, a feature of all Colley, 1989; Moremen et al., 1994). known Golgi processing enzymes. Southern blotting indi- Most information on the N-glycosylation pathway in lepi- cated that a-mannosidase II is a single copy gene in Sf9 dopteran insect cells has come from structural studies on for- cells. Other Lepidoptera had related a-mannosidase II eign glycoproteins expressed in baculovirus-infected cell lines genes, but there was variation among different genera, and or in larvae (reviewed by Jarvis and Summers, 1992; O'Reilly the Sf9 a-mannosidase II cDNA did not cross-hybridize et al., 1992; Jarvis, 1993a). These studies have demonstrated with DNA from animals outside Lepidoptera. Steady-state that lepidopteran insect cells have processing glucosidases and levels of a-mannosidase II RNA were low in uninfected Sf9 mannosidases which convert high mannose oligosaccharides to cells and even lower after baculovirus infection. The trimmed structures with as few as three mannose residues in v#ro-translated Sf9 a-mannosidase II protein had the (pauci-mannose structures). Several lines of evidence indicate expected size and was translocated and N-glycosylated by that these cells also have a fucosyltransferase that can add microsomal membranes. Expression of the Sf9 a-mannosi- fucose to the core Asn-linked GlcNAc residue (Staudacher et dase II cDNA in the baculovirus system produced large al., 1992), but it remains unclear whether insect cells have the amounts of a protein with the expected size and swainso- ability to extend these trimmed structures, as in mammalian nine-sensitive a-mannosidase II activity towards an aryl- cells. Most structural data indicate that baculovirus-expressed a-mannoside substrate. These results demonstrate that Sf9 glycoproteins (Kuroda et al., 1990; Chen and Bahl, 1991; Chen cells encode and express an a-mannosidase II with prop- etal., 1991; Wathen etal, 1991; Hogeland et al., 1992; Knep- erties similar to those of the mammalian enzyme. per et al., 1992; Grabenhorst et al., 1993; Yeh et al., 1993; Manneberg et al., 1994; Jarvis and Finn, 1995) and native Key words: class II ot-mannosidase/cDNA/lepidopteran insect insect glycoproteins (Butters et al, 1981; Hsieh and Robbins, cells/baculovirus expression system 1984; Ryan et al., 1985; Nagao et al., 1987; Williams et al., 1991) have only trimmed and fucosylated high mannose or © Oxford University Press 113 D.LJarvis et at pauci-mannose oligosaccharides. However, some recent stud- human a-mannosidase II (42.3% and 43.3% identity, respec- ies indicate that lepidopteran insect cell lines have GlcNAc tively) and D .discoideum and human lysosomal a-mannosi- transferase I and II activities (Altmann et al., 1993; Velardo et dase (29.4% and 26.1% identity, respectively), were identified al., 1993) and that they can produce glycoproteins with termi- by diis analysis. This suggested that the Sf9 amplimer was nal GlcNAc (Kubelka et al., 1994; Ackermann et al., 1995), derived from a gene that is related to the class II mannosidases Gal (Ogonah et al., 1996), and sialic acid (Davidson et al, and is more similar to the Golgi processing than the lysosomal 1990; Davidson and Castellino, 1991a). mannosidases. While structural biochemistry has provided much useful in- The Sf9 amplimer DNA sequence was used to design exact- formation on the N-glycosylation pathway in lepidopteran in- match primers against the putative Sf9 a-mannosidase II cod- sect cells, this approach is limited because it is indirect and ing region, and these primers were used for PCRs with total \ provides only a retrospective view of the processing pathway, DNA from an unfractionated Sf9 cDNA library, as described in which must be inferred from the structures of the end-products. Materials and methods. Electrophoretic analysis of the reaction Conclusions about the processing pathway can be complicated products revealed one major DNA fragment of about the same by degradative pathways, which might alter the product of the size as the RT-PCR product (data not shown). The same result biosynthetic pathway and lead to misinterpretations (Licari et was obtained with total A. DNA from an unfractionated Sf9 al., 1993; Jarvis and Finn, 1995). Finally, conclusions based on genomic DNA library or with the pCRII clone containing the Downloaded from https://academic.oup.com/glycob/article/7/1/113/725524 by guest on 01 October 2021 structural data from any one glycoprotein might apply only to Sf9 amplimer, but not in negative controls which lacked tem- that glycoprotein and not to the pathway in general. An alter- plate DNA or contained one specific and one nonspecific native approach that circumvents these problems is to use mo- primer (data not shown). These results indicated that the un- lecular genetics to isolate genes encoding glycoprotein pro- infected Sf9 cell cDNA library included a clone containing the cessing enzymes. This makes it possible to study these genes, putative Sf9 a-mannosidase II coding region, prompting us to their expression, and, ultimately, the properties of the enzymes proceed to isolate this cDNA by using a sibling selection and they encode. A large number of cDNAs encoding various gly- PCR screening approach (Moremen, 1989). Three positive coprotein processing enzymes have been cloned and charac- clones were isolated through sibling selection and three rounds terized in other systems (reviewed by Paulson and Colley, of plaque purification, as described in Materials and methods 1989; Lowe, 1991; Joziasse, 1992; Moremen etai, 1994; Field (data not shown). The cDNA inserts were excised
Recommended publications
  • Hexosaminidase in Mast Β Primary Role of Degranulation Indicator in Mast Cells?
    Does β-Hexosaminidase Function Only as a Degranulation Indicator in Mast Cells? The Primary Role of β-Hexosaminidase in Mast Cell Granules This information is current as of September 25, 2021. Nobuyuki Fukuishi, Shinya Murakami, Akane Ohno, Naoya Yamanaka, Nobuaki Matsui, Kenji Fukutsuji, Sakuo Yamada, Kouji Itoh and Masaaki Akagi J Immunol 2014; 193:1886-1894; Prepublished online 11 July 2014; Downloaded from doi: 10.4049/jimmunol.1302520 http://www.jimmunol.org/content/193/4/1886 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2014/07/11/jimmunol.130252 Material 0.DCSupplemental References This article cites 52 articles, 18 of which you can access for free at: http://www.jimmunol.org/content/193/4/1886.full#ref-list-1 Why The JI? Submit online. by guest on September 25, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2014 by The American Association of
    [Show full text]
  • Quality Assessment Enzyme Analysis for Lysosomal Storage Diseases ERNDIM / EUGT Meeting 5-6 October 2006, Prague
    QQuality Assessment Enzyme Analysis for Lysosomal Storage Diseases ERNDIM / EUGT meeting 5-6 October 2006, Prague Results of 1st “large scale” pilot Quality Assessment Enzyme Analysis for Lysosomal Storage Diseases Laboratories Rotterdam Hamburg/Heidelberg Dr, Zoltan Lukacs/Dr. Friederike Bürger QA-pilot for LSD’s the aims • Inter-laboratory variation ─ Many participants: > 30 • Intra-laboratory variation ─ Analyse two pairs of identical control samples (blind) • Proficiency testing of enzyme deficiencies ─ Which samples are best? - Blood samples: most widely used, but impractible - Fibroblasts: good but laborious - EBV lymphoblasts: easy to obtain, not widely used QA-pilot for LSD’s the set up • Samples, without clinical information ─ Leukocytes ─ EBV lymphoblasts ─ Fibroblasts • Enzymes: easy ones ─ 4MU-substrates ─ Simple colorimetric assays • Shipping: economic ─ Send at room temp., postal service - Lyophilised enzymes, stable at room temp. for 5 days - Fibroblasts • Data entry through existing ERNDIM programmes ─ “Metabolite presentation” (www.erndimqa.nl Æ Lysosomal Enzymes) QA-pilot for LSD’s the participants • Questionnaire to members (85 from 21 countries) ─ 40 labs want to join a QA-pilot ─ 65% want to include DBS in future QA-schemes • Samples sent, data returned ─ 40 labs received samples ─ 36 labs entered data on www.erndimqa.nl QA-pilot for LSD’s the samples • 10 samples ─ 4 leukocytes (two duplicate samples) ─ 4 EBV lymphoblasts ─ 2 fibroblasts • 10 easy enzymes ─ specific enzyme activity (e.g.. nmol/h/mg) ─ normalise to
    [Show full text]
  • Functional Characterization of Carbohydrate-Active Enzymes from Marine Bacteria
    Functional characterization of carbohydrate-active enzymes from marine bacteria I n a u g u r a l d i s s e r t a t i o n zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften (Dr. rer. nat.) der Mathematisch-Naturwissenschaftlichen Fakultät der Universität Greifswald vorgelegt von Marcus Bäumgen Greifswald, 28.02.2020 Dekan: Prof. Dr. Werner Weitschies 1. Gutachter: Prof. Dr. Uwe T. Bornscheuer 2. Gutachter: Prof. Dr. Harry Brumer Tag der Promotion: 24.06.2020 II III Wissenschaft ist das Werkzeug, welches es uns ermöglicht, das große Puzzel der Natur und des Lebens zu lösen. IV Auch wenn wir den Weg des Wissens und der Weisheit niemals bis zum Ende beschreiten können, so ist doch jeder Schritt, den wir tun, ein Schritt in eine bessere Welt. V Content Abbreviations ..................................................................................................................... IX 1. Introduction ..................................................................................................................... 1 1.1 The marine carbon cycle .............................................................................................. 1 1.1.1 Algal blooms .......................................................................................................... 1 1.1.2 The marine carbohydrates ulvan and xylan ........................................................... 2 1.1.3 Marine polysaccharide utilization ........................................................................... 4 1.2 Carbohydrate-active enzymes
    [Show full text]
  • The Metabolism of Tay-Sachs Ganglioside: Catabolic Studies with Lysosomal Enzymes from Normal and Tay-Sachs Brain Tissue
    The Metabolism of Tay-Sachs Ganglioside: Catabolic Studies with Lysosomal Enzymes from Normal and Tay-Sachs Brain Tissue JOHN F. TALLMAN, WILLIAM G. JOHNSON, and ROSCOE 0. BRADY From the Developmental and Metabolic Neurology Branch, National Institute of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, Maryland 20014, and the Department of Biochemistry, Georgetown University School of Medicine, Washington, D. C. 20007 A B S T R A C T The catabolism of Tay-Sachs ganglioside, date fronm the 19th century and over 599 cases have been N-acetylgalactosaminyl- (N-acetylneuraminosyl) -galac- reported (1). Onset of the disease is in the first 6 months tosylglucosylceramide, has been studied in lysosomal of life and is characterized by apathy, hyperacusis, motor preparations from normal human brain and brain ob- weakness, and appearance of a macular cherry-red spot tained at biopsy from Tay-Sachs patients. Utilizing Tay- in the retina. Seizures and progressive mental deteriora- Sachs ganglioside labeled with '4C in the N-acetylgalac- tion follow with blindness, deafness, and spasticity, lead- tosaminyl portion or 3H in the N-acetylneuraminosyl ing to a state of decerebrate rigidity. These infants usu- portion, the catabolism of Tay-Sachs ganglioside may be ally die by 3 yr of age (2). initiated by either the removal of the molecule of A change in the chemical composition of the brain of N-acetylgalactosamine or N-acetylneuraminic acid. The such patients was first detected by Klenk who showed activity of the N-acetylgalactosamine-cleaving enzyme that there was an increase in the ganglioside content (hexosaminidase) is drastically diminished in such compared with normal human brain tissue (3).
    [Show full text]
  • GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies
    International Journal of Molecular Sciences Review GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies Andrés Felipe Leal 1 , Eliana Benincore-Flórez 1, Daniela Solano-Galarza 1, Rafael Guillermo Garzón Jaramillo 1 , Olga Yaneth Echeverri-Peña 1, Diego A. Suarez 1,2, Carlos Javier Alméciga-Díaz 1,* and Angela Johana Espejo-Mojica 1,* 1 Institute for the Study of Inborn Errors of Metabolism, Faculty of Science, Pontificia Universidad Javeriana, Bogotá 110231, Colombia; [email protected] (A.F.L.); [email protected] (E.B.-F.); [email protected] (D.S.-G.); [email protected] (R.G.G.J.); [email protected] (O.Y.E.-P.); [email protected] (D.A.S.) 2 Faculty of Medicine, Universidad Nacional de Colombia, Bogotá 110231, Colombia * Correspondence: [email protected] (C.J.A.-D.); [email protected] (A.J.E.-M.); Tel.: +57-1-3208320 (ext. 4140) (C.J.A.-D.); +57-1-3208320 (ext. 4099) (A.J.E.-M.) Received: 6 July 2020; Accepted: 7 August 2020; Published: 27 August 2020 Abstract: GM2 gangliosidoses are a group of pathologies characterized by GM2 ganglioside accumulation into the lysosome due to mutations on the genes encoding for the β-hexosaminidases subunits or the GM2 activator protein. Three GM2 gangliosidoses have been described: Tay–Sachs disease, Sandhoff disease, and the AB variant. Central nervous system dysfunction is the main characteristic of GM2 gangliosidoses patients that include neurodevelopment alterations, neuroinflammation, and neuronal apoptosis. Currently, there is not approved therapy for GM2 gangliosidoses, but different therapeutic strategies have been studied including hematopoietic stem cell transplantation, enzyme replacement therapy, substrate reduction therapy, pharmacological chaperones, and gene therapy.
    [Show full text]
  • Mannoside Recognition and Degradation by Bacteria Simon Ladeveze, Elisabeth Laville, Jordane Despres, Pascale Mosoni, Gabrielle Veronese
    Mannoside recognition and degradation by bacteria Simon Ladeveze, Elisabeth Laville, Jordane Despres, Pascale Mosoni, Gabrielle Veronese To cite this version: Simon Ladeveze, Elisabeth Laville, Jordane Despres, Pascale Mosoni, Gabrielle Veronese. Mannoside recognition and degradation by bacteria. Biological Reviews, Wiley, 2016, 10.1111/brv.12316. hal- 01602393 HAL Id: hal-01602393 https://hal.archives-ouvertes.fr/hal-01602393 Submitted on 26 May 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Biol. Rev. (2016), pp. 000–000. 1 doi: 10.1111/brv.12316 Mannoside recognition and degradation by bacteria Simon Ladeveze` 1, Elisabeth Laville1, Jordane Despres2, Pascale Mosoni2 and Gabrielle Potocki-Veron´ ese` 1∗ 1LISBP, Universit´e de Toulouse, CNRS, INRA, INSA, 31077, Toulouse, France 2INRA, UR454 Microbiologie, F-63122, Saint-Gen`es Champanelle, France ABSTRACT Mannosides constitute a vast group of glycans widely distributed in nature. Produced by almost all organisms, these carbohydrates are involved in numerous cellular processes, such as cell structuration, protein maturation and signalling, mediation of protein–protein interactions and cell recognition. The ubiquitous presence of mannosides in the environment means they are a reliable source of carbon and energy for bacteria, which have developed complex strategies to harvest them.
    [Show full text]
  • J. Biol. Chem. Published Online December 22, 2019
    This is a repository copy of Structure and function of Bs164 β-mannosidase from Bacteroides salyersiae the founding member of glycoside hydrolase family GH164. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/155946/ Version: Accepted Version Article: Armstrong, Zachary and Davies, Gideon J orcid.org/0000-0002-7343-776X (2020) Structure and function of Bs164 β-mannosidase from Bacteroides salyersiae the founding member of glycoside hydrolase family GH164. The Journal of biological chemistry. pp. 4316-4326. ISSN 1083-351X https://doi.org/10.1074/jbc.RA119.011591 Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ JBC Papers in Press. Published on December 22, 2019 as Manuscript RA119.011591 The latest version is at http://www.jbc.org/cgi/doi/10.1074/jbc.RA119.011591 Structure and Function of Bs164 Structure and function of Bs164 β-mannosidase from Bacteroides salyersiae the founding member of glycoside hydrolase family GH164.
    [Show full text]
  • Pompe Disease
    Substrate Localisation as a Therapeutic Option for Pompe Disease A thesis submitted to The University of Adelaide for the degree of DOCTOR OF PHILOSOPHY by Christopher Travis Turner, BBtech (Hons) Lysosomal Diseases Research Unit Department of Genetic Medicine Women’s & Children’s Hospital North Adelaide, South Australia, 5006 October 2013 Paediatrics Paediatrics and Reproductive Health The University of Adelaide 1 Table of Contents Abstract 7 Declaration of authenticity 9 Acknowledgments 10 Abbreviations 11 List of figures 15 List of tables 18 Chapter 1 – Introduction 19 1.1 The endosome-lysosome System 20 1.1.1 The endosome 20 1.1.2 The lysosome 25 1.1.3 Autophagosomes 28 1.2 Pompe disease 36 1.2.1 Incidence 37 1.2.2 Clinical manifestations 37 1.2.3 Genetics 39 1.2.4 Diagnosis 41 1.2.5 Lysosomal acid α-glucosidase (GAA) 42 1.2.6 Glycogen synthesis and metabolism 44 1.2.6.1 Glycogen synthesis 46 1.2.6.2 Glycogen catabolism 49 2 1.2.6.3 Autophagy and lysosomal degradation of glycogen 50 1.2.7 Glycogen accumulation in Pompe disease 52 1.2.8 Treatment of Pompe disease 54 1.2.8.1 Gene therapy 54 1.2.8.2 Chaperone therapy 55 1.2.8.3 Enzyme replacement therapy 56 1.3 Exocytosis 60 1.3.1 Ca2+-dependent exocytosis 62 1.3.2 Exocytic mechanism 64 1.3.3 All-or-none exocytosis 66 1.3.4 Cavicapture 66 1.3.5 The contribution of all-or-none exocytosis and cavicapture to the overall amount of exocytosis 67 1.3.6 Evidence for the exocytosis of glycogen in Pompe disease 68 1.4 Hypothesis and aims 70 Chapter 2 – Materials and Methods 71 2.1 Materials 72
    [Show full text]
  • Glycosphingolipids Are Modulators of Disease Pathogenesis in Amyotrophic Lateral Sclerosis
    Glycosphingolipids are modulators of disease pathogenesis in amyotrophic lateral sclerosis James C. Dodgea,1, Christopher M. Treleavena, Joshua Pachecoa, Samantha Coopera,ChannaBaoa, Marissa Abrahama, Mandy Cromwella, S. Pablo Sardia, Wei-Lien Chuanga, Richard L. Sidmanb,1,2,SengH.Chenga, and Lamya S. Shihabuddina aRare Diseases Science, Genzyme, a Sanofi Company, Framingham, MA 01701; and bBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215 Contributed by Richard L. Sidman, May 7, 2015 (sent for review January 12, 2015; reviewed by David V. Schaffer) Recent genetic evidence suggests that aberrant glycosphingolipid mediates the hydrolysis of Cer, are linked to forms of spinal metabolism plays an important role in several neuromuscular muscular atrophy that are not caused by the more frequent mu- diseases including hereditary spastic paraplegia, hereditary sen- tations in the survival motor neuron 1 gene (non-5q SMA) (15). sory neuropathy type 1, and non-5q spinal muscular atrophy. Here, Moreover, hereditary spastic paraplegia (HSP), a disease with cor- we investigated whether altered glycosphingolipid metabolism is ticospinal tract and in some cases, spinal cord MN degeneration, a modulator of disease course in amyotrophic lateral sclerosis (ALS). is attributed to mutations in GM2 synthase (16) and the non- Levels of ceramide, glucosylceramide, galactocerebroside, lactosyl- lysosomal glucosylceramidase, GBA2 (17). Last, patients with adult- ceramide, globotriaosylceramide, and the gangliosides GM3 and onset Tay-Sachs disease (GM2 gangliosidosis), a disease triggered GM1 were significantly elevated in spinal cords of ALS patients. by a deficiency in hexosaminidase (HEX), a lysosomal enzyme Moreover, enzyme activities (glucocerebrosidase-1, glucocerebrosi- that hydrolyzes GM2 to GM3, have been reported in some in- dase-2, hexosaminidase, galactosylceramidase, α-galactosidase, and stances to display a disease phenotype that closely mimics ALS β-galactosidase) mediating glycosphingolipid hydrolysis were also (18–20).
    [Show full text]
  • ZHOU-THESIS-2018.Pdf (2.307Mb)
    PHYLOGENY AND PREDICTED FUNCTIONAL CAPABILITIES OF A SULFUR- OXIDIZING AND DENITRIFYING CLADE OF BACTEROIDETES FROM SULFIDIC ENVIRONMENTS A Thesis by KECEN ZHOU Submitted to the Office of Graduate and Professional Studies of Texas A&M University in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Chair of Committee, Jason B. Sylvan Co-Chair of Committee, Lisa Campbell Committee Member, Brendan E. Roark Head of Department, Shari Yvon-Lewis August 2018 Major Subject: Oceanography Copyright 2018 Kecen Zhou ABSTRACT Environments rich in sulfur compounds (sulfidic) are common in the ocean, and the ability to gain energy (dissimilatory) from sulfur redox reactions is widespread in bacteria. The Sulfiphilic Bacteroidetes (SB), have been found exclusively in sulfidic environments, but little is known about their metabolic potential and membership. The ability to perform dissimilatory sulfur redox would make them unique among Bacteroidetes, which are primarily known as heterotrophs that specialize in degrading complex organic molecules. Using 16S rRNA phylogeny and analysis of single amplified genomes (SAGs) from Saanich Inlet, a seasonally hypoxic basin, we elucidate the global distribution and potential metabolic capabilities of the SB clade. Phylogenetic analysis revealed that this clade was monophyletic and had a global distribution. It is hypothesized this clade combines heterotrophic amino acid and sugar uptake with denitrification and respiratory sulfur oxidation/polysulfide reduction. Putative genes for sulfur oxidation via polysulfide reductase (psr) were found in the combined genome, and phylogenetic analysis confirmed these genes were likely to be psrABC. A denitrification pathway was present and complete save for the absence of a gene catalyzing reduction of NO to N2O.
    [Show full text]
  • Tay-Sachs Disease with Altered P-Hexosaminidase B: a New Variant?
    Pediat . Res. 12: 77-81 (1978) N-Acetyl P-D-hexosaminidase (Hex) heat lability Tay-Sachs disease Tay-Sachs Disease with Altered P-Hexosaminidase B: A New Variant? TORU ~0~01:~~'MASAKATSU SUDO, KENICHI TANIOKA, AND YASUJI NAKAO Department of Pediatrics, School of Medicine, Kyoto University, Kyoto, Japan SHlNlCHl HARUKl Department of Pediatrics, Himeji National Hospital, Himeji, Japan Summary its carriers, and patients with partial Hex A deficiency. Patients with partial Hex A deficiency are distinguishable from those A 2.5-year-old Japanese girl who showed signs and symptoms with ciassic TSD as the onset is later and the course milder (2, compatible with classic Tay-Sachs disease and had 'altered P- . "14, 23, 28). hexosaminidase B and I, as well as completely deficient P- We encountered a Japanese girl who showed signs and hexosaminidase A activity is reported herein. symptoms compatible with classic TSD. Hex A activities in Heat treatment of the patient's serum and leukocyte samples serum samples, as detected by the heat-inactivation method, showed the existence of 13.5-27.3% and 35.7% of the heat- revealed partial deficiency in this isozyme. As there is apparently labile component of P-hexosaminidase, respectively, such is no documentation concerning classic TSD with partial Hex A usually considered to correspond to /3-hexosaminidase A. The deficiency, we investigated the nature of the heat lability of absence of Phexosaminidase A activity was confirmed by Hex in our patient and the findings are reported herein. DEAE-cellulose column chromatography and cellulose acetate paper electrophoresis. The patient's serum P-hexosaminidase also contained a significant amount of acid pH-labile compo- CASE REPORT nents.
    [Show full text]
  • New Approaches to Correcting Metabolic Errors in Tay-Sachs
    New Approaches to Correcting Metabolic Errors in Tay-Sachs New Approaches to Correcting Metabolic Errors in Tay-Sachs Katherine Stefanski Abstract Tay-Sachs Disease (TSD) is a neurodegenerative disorder categorized as both a gangliosidosis and a lysosomal storage disease. Tay-Sachs is caused by a deficiency in the enzymeβ -hexosaminidase A (Hex A). There is no current remedy available for TSD. However, there have been promising studies and breakthroughs on the use of gene therapy to cure Tay-Sachs, and these studies will be discussed in this review article. Initial progress was made using a cell line model for TSD which led to subsequent studies in HEXA null knock-out mice and mice with Sandhoff disease (a related disease involving the same enzyme). Eventually, researchers were able to transduce the brain of Sandhoff mice correcting the diseases neurological symptoms. Most recently, felines with Sandhoff disease were also successfully treated with gene therapy. Advances made in lifespan, quality of life, and relative safety of the treatment in animal models implies a readiness for human trials. Middle Tennessee State University 43 Scientia et Humanitas: A Journal of Student Research Introduction Background ay-Sachs disease (TSD), named for the two physicians who first described it, was discovered by Warren Tay, a British ophthalmologist, and Bernard Sachs, a neurologistT from New York City. The disease presents beginning around six months of age with early blindness, severe mental retardation, paralysis, and in most cases death early in childhood before four years of age. It is most commonly seen in children of Eastern Eu- ropean Ashkenazi Jewish descent as well as some French Canadian and Louisiana Cajun populations.1 TSD is an autosomal recessive disorder caused by a mutation in the gene that encodes for the lysosomal enzyme β-hexosaminidase A (Hex A), HEXA.2 Metabolic Basis of Tay-Sachs TSD is classified as both a gangliosidosis and a lysosomal storage disease.2,3 Ganglio- sides are the principal glycolipid comprising neuronal plasma membranes.
    [Show full text]